Hydroxycarbamide

Articles · Medicine Compliance Aid Stability · Lactation Safety Information · New Medicines ·
56602009

Articles

Safety in Lactation: Other antineoplastic drugs

Antineoplastic agents, whether used as monotherapy or in combination with other antineoplastics, are contra-indicated in breastfeeding (unless indicated below) because of their effects on dividing… Amsacrine Arsenic Asparaginase Bevacizumab Bortezomib Brentuximab vedotin Catumaxomab Cetuximab Dacarbazine Eribulin Hydroxycarbamide Ipilimumab Irinotecan Mitotane Panitumumab Pentostatin Pertuzumab Porfimer Topotecan Trabectedin Trastuzumab Tretinoin

Medicine Compliance Aid Stability

Siklos · Nordic Pharma Ltd

Nordic Pharma Ltd
Siklos
Tablets f/c 100mg, 1000mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Store in airtight containers, in a dry atmosphere, protect from light. Decomposes in the presence of moisture. Cytotoxic and package contains dessicant.
29th March 2015

Lactation Safety Information

Hydroxyurea

Hydroxyurea
Serious adverse effects reported in adults
Very limited published evidence of safety

Hydroxyurea for sickle-cell disease

Hydroxyurea for sickle-cell disease
Serious adverse effects reported in adults
Very limited published evidence of safety

New Medicines

Xromi · Prevention of vaso-occlusive complications in patients with sickle cell disease aged >2 years - oral solution formulation

Information

Xromi
New formulation
Nova Laboratories
Not Known

Development and Regulatory status

Launched
Launched
None
March 2020
Mar 20 · Price for 100mg/ml liquid, 150ml = £250 [6].
Mar 20 · Available in the UK. The 100mg/ml liquid has an expiry date of 2 years and an in-use shelf life of 12 weeks. It is lactose, alcohol and sugar free and must be stored in the fridge [5].
Nov 19 · Available to the UK early next year, with launches in Ireland and some countries in Europe planned [4].
Sep 19 · Planned to launch in November 2019. Price 1 x 150ml = £250. There will a reduced special price for the NHS [3].
Jul 19 · Approved in the EU for prevention of vaso-occlusive complications of SCD in patients aged>2 years [2]

Category

Orally active antineoplastic agent. In SCD, hydroxycarbamide elevates HbF concentrations. HbF interferes with the polymerisation of HbS (sickle haemoglobin) and so impedes the sickling of red blood cell.
Sickle cell disease is thought to be the most common severe genetic disease in the UK and France, with 10,000-15,000 people affected. Vaso-occlusive crises (obstruction of the microcirculation by sickled red blood cells, causing ischaemia) is the most common type of crisis. It may be precipitated by cold, infection, dehydration, exertion or ischaemia. Often no specific cause can be found [1].
Prevention of vaso-occlusive complications in patients with sickle cell disease aged >2 years - oral solution formulation
Oral